$VCEL
Vericel Corp Stock $vcel

$vcel Overview Financials Valuation SEC Filings Company Website

2018 Q4 Form 10-Q Financial Statement

#000162828018013767 Filed on November 06, 2018

Income Statement

Concept	2018 Q4	2018 Q3	2017 Q4
Revenue	$31.34M	$22.48M	$23.35M
YoY Change	34.2%	57.67%	0.0%
Cost Of Revenue	$8.630M	$8.140M	$8.390M
YoY Change	2.86%	13.28%	10.54%
Gross Profit	$22.71M	$14.35M	$14.96M
YoY Change	51.77%	102.8%	0.0%
Gross Profit Margin	72.46%	63.81%	64.07%
Selling, General & Admin	$13.69M	$12.57M	$10.18M
YoY Change	34.48%	53.54%	28.37%
% of Gross Profit	60.29%	87.61%	68.04%
Research & Development	$3.020M	$3.113M	$3.590M
YoY Change	-15.88%	6.65%	-15.73%
% of Gross Profit	13.3%	21.7%	24.0%
Depreciation & Amortization	$300.0K	$320.0K	$420.0K
YoY Change	-28.57%	-21.95%	-16.0%
% of Gross Profit	1.32%	2.23%	2.81%
Operating Expenses	$16.71M	$15.68M	$13.77M
YoY Change	21.35%	41.22%	13.05%
Operating Profit	$5.995M	-$1.336M	$1.191M
YoY Change	403.36%	-66.86%	0.0%
Interest Expense	$160.0K	$460.0K	$50.00K
YoY Change	220.0%	45.11%	-116.13%
% of Operating Profit	2.67%		4.2%
Other Income/Expense, Net	-$80.00K	$267.0K	-$100.0K
YoY Change	-20.0%	-119.4%
Pretax Income	$5.240M	-$1.070M	$290.0K
YoY Change	1706.9%	-80.22%	-104.68%
Income Tax			$0.00
% Of Pretax Income			0.0%
Net Earnings	$5.242M	-$1.069M	$287.0K
YoY Change	1726.48%	-80.23%	0.0%
Net Earnings / Revenue	16.73%	-4.75%	1.23%
Basic Earnings Per Share	$0.12	-$0.02
Diluted Earnings Per Share	$0.11	-$0.02	$8.269K
COMMON SHARES
Basic Shares Outstanding	43.35M shares	42.93M shares	34.91M shares
Diluted Shares Outstanding		42.93M shares

Balance Sheet

Concept	2018 Q4	2018 Q3	2017 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$82.90M	$97.80M	$26.90M
YoY Change	208.18%	530.97%	16.96%
Cash & Equivalents	$18.29M	$53.29M	$26.86M
Short-Term Investments	$64.60M	$44.50M
Other Short-Term Assets	$2.847M	$2.339M	$1.581M
YoY Change	80.08%	71.23%	35.82%
Inventory	$3.558M	$3.638M	$3.793M
Prepaid Expenses
Receivables	$23.45M	$15.53M	$18.27M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$112.8M	$119.3M	$50.51M
YoY Change	123.31%	228.43%	12.93%
LONG-TERM ASSETS
Property, Plant & Equipment	$5.906M	$5.207M	$4.071M
YoY Change	45.07%	31.26%	5.06%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$5.906M	$5.207M	$4.071M
YoY Change	45.07%	31.26%	5.06%
TOTAL ASSETS
Total Short-Term Assets	$112.8M	$119.3M	$50.51M
Total Long-Term Assets	$5.906M	$5.207M	$4.071M
Total Assets	$118.7M	$124.5M	$54.58M
YoY Change	117.47%	209.01%	12.3%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$7.108M	$4.580M	$5.552M
YoY Change	28.03%	-23.31%	-15.04%
Accrued Expenses	$6.930M	$5.600M	$5.573M
YoY Change	24.35%	1377.57%	23.21%
Deferred Revenue		$534.0K	$420.0K
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$0.00	$4.100M	$400.0K
YoY Change	-100.0%	57.69%	-50.0%
Total Short-Term Liabilities	$14.79M	$14.99M	$13.09M
YoY Change	13.0%	3.19%	1.84%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$13.18M	$16.89M
YoY Change	-100.0%	78.15%	81.24%
Other Long-Term Liabilities	$1.666M	$1.800M	$2.100M
YoY Change	-20.67%		6462.5%
Total Long-Term Liabilities	$1.666M	$13.18M	$2.059M
YoY Change	-19.09%	78.15%	22.05%
TOTAL LIABILITIES
Total Short-Term Liabilities	$14.79M	$14.99M	$13.09M
Total Long-Term Liabilities	$1.666M	$13.18M	$2.059M
Total Liabilities	$16.46M	$29.99M	$32.04M
YoY Change	-48.63%	27.39%	34.1%
SHAREHOLDERS EQUITY
Retained Earnings	-$369.0M	-$374.3M	-$360.9M
YoY Change	2.25%	3.62%	5.03%
Common Stock	$471.2M	$468.4M	$383.0M
YoY Change	23.02%	24.02%	16.17%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$102.2M	$94.48M	$22.54M
YoY Change
Total Liabilities & Shareholders Equity	$118.7M	$124.5M	$54.58M
YoY Change	117.47%	209.01%	12.3%

Cashflow Statement

Concept	2018 Q4	2018 Q3	2017 Q4
OPERATING ACTIVITIES
Net Income	$5.242M	-$1.069M	$287.0K
YoY Change	1726.48%	-80.23%	0.0%
Depreciation, Depletion And Amortization	$300.0K	$320.0K	$420.0K
YoY Change	-28.57%	-21.95%	-16.0%
Cash From Operating Activities	$2.610M	$2.020M	$840.0K
YoY Change	210.71%	-138.55%	-109.02%
INVESTING ACTIVITIES
Capital Expenditures	-$580.0K	-$1.120M	-$720.0K
YoY Change	-19.44%	115.38%	554.55%
Acquisitions
YoY Change
Other Investing Activities	-$19.87M	-$44.48M	$0.00
YoY Change
Cash From Investing Activities	-$20.45M	-$45.60M	-$720.0K
YoY Change	2740.28%	8669.23%	554.55%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-17.17M	1.910M	11.28M
YoY Change	-252.22%	-73.44%	-52.0%
NET CHANGE
Cash From Operating Activities	2.610M	2.020M	840.0K
Cash From Investing Activities	-20.45M	-45.60M	-720.0K
Cash From Financing Activities	-17.17M	1.910M	11.28M
Net Change In Cash	-35.01M	-41.67M	11.40M
YoY Change	-407.11%	-3013.99%	-19.03%
FREE CASH FLOW
Cash From Operating Activities	$2.610M	$2.020M	$840.0K
Capital Expenditures	-$580.0K	-$1.120M	-$720.0K
Free Cash Flow	$3.190M	$3.140M	$1.560M
YoY Change	104.49%	-166.53%	-116.96%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	19000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	793000	USD
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	148000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	202000	USD
	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	758000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	129000	USD
	us-gaap	Increase Decrease In Other Operating Capital Net IncreaseDecreaseInOtherOperatingCapitalNet	-74000	USD
	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	-91000	USD
	us-gaap	Increase Decrease In Prepaid Rent IncreaseDecreaseInPrepaidRent	132000	USD
CY2017Q3	astm	Depreciation Depletionand Amortization Excluding Intangible Assets DepreciationDepletionandAmortizationExcludingIntangibleAssets	400000	USD
	astm	Depreciation Depletionand Amortization Excluding Intangible Assets DepreciationDepletionandAmortizationExcludingIntangibleAssets	1200000	USD
CY2018Q3	astm	Depreciation Depletionand Amortization Excluding Intangible Assets DepreciationDepletionandAmortizationExcludingIntangibleAssets	300000	USD
	astm	Depreciation Depletionand Amortization Excluding Intangible Assets DepreciationDepletionandAmortizationExcludingIntangibleAssets	1100000	USD
CY2017Q4	astm	Lineof Creditand Term Loan Credit Agreement Current Netof Deferred Costs LineofCreditandTermLoanCreditAgreementCurrentNetofDeferredCosts	350000	USD
CY2018Q3	astm	Lineof Creditand Term Loan Credit Agreement Current Netof Deferred Costs LineofCreditandTermLoanCreditAgreementCurrentNetofDeferredCosts	4097000	USD
CY2018Q3	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDue	40981000	USD
CY2018Q3	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due Current OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueCurrent	2613000	USD
CY2018Q3	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Four Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInFourYears	13394000	USD
CY2018Q3	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Three Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInThreeYears	11400000	USD
CY2018Q3	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due In Two Years OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueInTwoYears	11909000	USD
CY2018Q3	astm	Operatingand Capital Leasesand Purchase Commitments Future Minimum Payments Due Thereafter OperatingandCapitalLeasesandPurchaseCommitmentsFutureMinimumPaymentsDueThereafter	64000	USD
	astm	Warrants Exercised For Common Stock WarrantsExercisedForCommonStock	0	USD
	astm	Warrants Exercised For Common Stock WarrantsExercisedForCommonStock	3538000	USD
	dei	Amendment Flag AmendmentFlag	false
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q3
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2018
	dei	Document Period End Date DocumentPeriodEndDate	2018-09-30
	dei	Document Type DocumentType	10-Q
	dei	Entity Central Index Key EntityCentralIndexKey	0000887359
CY2018Q4	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	43347348	shares
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Filer Category EntityFilerCategory	Accelerated Filer
	dei	Entity Registrant Name EntityRegistrantName	Vericel Corp
	dei	Entity Small Business EntitySmallBusiness	true
CY2017Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5573000	USD
CY2018Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	5592000	USD
CY2017Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	5552000	USD
CY2018Q3	us-gaap	Accounts Payable Current AccountsPayableCurrent	4580000	USD
CY2017Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	18270000	USD
CY2018Q3	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	15528000	USD
CY2017Q4	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	2693000	USD
CY2018Q3	us-gaap	Accrued Bonuses Current And Noncurrent AccruedBonusesCurrentAndNoncurrent	2180000	USD
CY2017Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	6621000	USD
CY2018Q3	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	7212000	USD
CY2017Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2018Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-18000	USD
CY2017Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	755000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2053000	USD
CY2018Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1932000	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5739000	USD
CY2017Q4	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	249000	USD
CY2018Q3	us-gaap	Allowance For Doubtful Accounts Receivable AllowanceForDoubtfulAccountsReceivable	286000	USD
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5400000	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5300000	shares
CY2017Q4	us-gaap	Assets Assets	54577000	USD
CY2018Q3	us-gaap	Assets Assets	124463000	USD
CY2017Q4	us-gaap	Assets Current AssetsCurrent	50506000	USD
CY2018Q3	us-gaap	Assets Current AssetsCurrent	119256000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	18000	USD
CY2018Q3	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	75180000	USD
CY2018Q3	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	75162000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	486000	USD
	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	191000	USD
CY2016Q4	us-gaap	Cash Cash	22978000	USD
CY2017Q3	us-gaap	Cash Cash	15466000	USD
CY2017Q4	us-gaap	Cash Cash	26862000	USD
CY2018Q3	us-gaap	Cash Cash	53289000	USD
CY2017Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	26862000	USD
CY2018Q3	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53289000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-7512000	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	26427000	USD
CY2017Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2018Q3	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2017Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2018Q3	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	75000000	shares
CY2017Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	35861000	shares
CY2018Q3	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	43170000	shares
CY2017Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	35861000	shares
CY2018Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	43170000	shares
CY2017Q4	us-gaap	Common Stock Value CommonStockValue	383020000	USD
CY2018Q3	us-gaap	Common Stock Value CommonStockValue	468447000	USD
CY2017Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-5407000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-17573000	USD
CY2018Q3	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1087000	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-13397000	USD
CY2017Q4	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	420000	USD
CY2018Q3	us-gaap	Contract With Customer Liability Current ContractWithCustomerLiabilityCurrent	534000	USD
CY2018Q3	us-gaap	Contractual Obligation ContractualObligation	20860000	USD
CY2018Q3	us-gaap	Contractual Obligation Due After Fifth Year ContractualObligationDueAfterFifthYear	0	USD
CY2018Q3	us-gaap	Contractual Obligation Due In Fifth Year ContractualObligationDueInFifthYear	0	USD
CY2018Q3	us-gaap	Contractual Obligation Due In Fourth Year ContractualObligationDueInFourthYear	7939000	USD
CY2018Q3	us-gaap	Contractual Obligation Due In Next Twelve Months ContractualObligationDueInNextTwelveMonths	814000	USD
CY2018Q3	us-gaap	Contractual Obligation Due In Second Year ContractualObligationDueInSecondYear	6290000	USD
CY2018Q3	us-gaap	Contractual Obligation Due In Third Year ContractualObligationDueInThirdYear	5817000	USD
CY2017Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	67000	USD
CY2018Q3	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	69000	USD
CY2017Q4	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	196000	USD
CY2018Q3	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	150000	USD
CY2018Q3	us-gaap	Deferred Rent Credit DeferredRentCredit	1900000	USD
CY2017Q4	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	2059000	USD
CY2018Q3	us-gaap	Deferred Rent Credit Noncurrent DeferredRentCreditNoncurrent	1813000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1186000	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1133000	USD
CY2017Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	1014000	USD
CY2018Q3	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	0	USD
CY2017Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.16
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.54
CY2018Q3	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.02
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.34
CY2017Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2389000	USD
CY2018Q3	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2955000	USD
CY2017Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	1060000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	512000	USD
CY2018Q3	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	-420000	USD
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2524000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-20000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-49000	USD
CY2017Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-6000	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-20000	USD
CY2018Q3	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	0	USD
	us-gaap	Foreign Currency Transaction Gain Loss Realized ForeignCurrencyTransactionGainLossRealized	-49000	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	0	USD
	us-gaap	Gain Loss On Disposition Of Assets1 GainLossOnDispositionOfAssets1	-23000	USD
CY2017Q3	us-gaap	Gross Profit GrossProfit	7074000	USD
	us-gaap	Gross Profit GrossProfit	18609000	USD
CY2018Q3	us-gaap	Gross Profit GrossProfit	14346000	USD
	us-gaap	Gross Profit GrossProfit	35991000	USD
CY2018Q3	us-gaap	Incentive From Lessor IncentiveFromLessor	2000000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1068000	USD
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1212000	USD
	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-9000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-1663000	USD
	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	-2742000	USD
CY2017Q3	us-gaap	Interest Expense InterestExpense	317000	USD
	us-gaap	Interest Expense InterestExpense	878000	USD
CY2018Q3	us-gaap	Interest Expense InterestExpense	460000	USD
	us-gaap	Interest Expense InterestExpense	1340000	USD
	us-gaap	Interest Paid Net InterestPaidNet	691000	USD
	us-gaap	Interest Paid Net InterestPaidNet	1161000	USD
CY2017Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	35000	USD
CY2018Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	52000	USD
CY2017Q4	us-gaap	Inventory Net InventoryNet	3793000	USD
CY2018Q3	us-gaap	Inventory Net InventoryNet	3638000	USD
CY2017Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3532000	USD
CY2018Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	3130000	USD
CY2017Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	226000	USD
CY2018Q3	us-gaap	Inventory Work In Process InventoryWorkInProcess	456000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	232000	USD
	us-gaap	Inventory Write Down InventoryWriteDown	303000	USD
CY2017Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	2000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	6000	USD
CY2018Q3	us-gaap	Investment Income Interest InvestmentIncomeInterest	307000	USD
	us-gaap	Investment Income Interest InvestmentIncomeInterest	390000	USD
CY2017Q4	us-gaap	Liabilities Liabilities	32037000	USD
CY2018Q3	us-gaap	Liabilities Liabilities	29988000	USD
CY2017Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	54577000	USD
CY2018Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	124463000	USD
CY2017Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13090000	USD
CY2018Q3	us-gaap	Liabilities Current LiabilitiesCurrent	14992000	USD
CY2017Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16888000	USD
CY2018Q3	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	13183000	USD
CY2018Q3	us-gaap	Minimum Lease Payments Sale Leaseback Transactions Due In Rolling After Year Five MinimumLeasePaymentsSaleLeasebackTransactionsDueInRollingAfterYearFive	1601000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	7297000	USD
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	76031000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-792000	USD
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-46581000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-14017000	USD
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-3023000	USD
CY2017Q3	us-gaap	Net Income Loss NetIncomeLoss	-5407000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-17573000	USD
CY2018Q3	us-gaap	Net Income Loss NetIncomeLoss	-1069000	USD
	us-gaap	Net Income Loss NetIncomeLoss	-13379000	USD
CY2017Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1376000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1398000	USD
CY2018Q3	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	267000	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-3475000	USD
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2017Q3	us-gaap	Operating Expenses OperatingExpenses	11105000	USD
	us-gaap	Operating Expenses OperatingExpenses	34784000	USD
CY2018Q3	us-gaap	Operating Expenses OperatingExpenses	15682000	USD
	us-gaap	Operating Expenses OperatingExpenses	45895000	USD
CY2017Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-4031000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-16175000	USD
CY2018Q3	us-gaap	Operating Income Loss OperatingIncomeLoss	-1336000	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-9904000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	16915000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Five Years OperatingLeasesFutureMinimumPaymentsDueInFiveYears	957000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	4811000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	4902000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	4908000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Due Thereafter OperatingLeasesFutureMinimumPaymentsDueThereafter	64000	USD
CY2018Q3	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	1273000	USD
CY2017Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1500000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4100000	USD
CY2018Q3	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	1300000	USD
	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	4100000	USD
CY2017Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	491000	USD
CY2018Q3	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	457000	USD
CY2017Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1581000	USD
CY2018Q3	us-gaap	Other Assets Current OtherAssetsCurrent	2339000	USD
CY2017Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	0	USD
CY2018Q3	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-18000	USD
	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	-18000	USD
CY2017Q4	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	181000	USD
CY2018Q3	us-gaap	Other Liabilities Current OtherLiabilitiesCurrent	189000	USD
CY2017Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	5000	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	6000	USD
CY2018Q3	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	USD
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	48000	USD
	us-gaap	Payments To Acquire Available For Sale Securities Debt PaymentsToAcquireAvailableForSaleSecuritiesDebt	10000000	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	0	USD
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	44480000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	792000	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	2101000	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	0	USD
	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	70028000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-252000	USD
	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-23000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	7549000	USD
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	3310000	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	0	USD
	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	2716000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	10692000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12419000	USD
CY2017Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4071000	USD
CY2018Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	5207000	USD
CY2018Q3	us-gaap	Purchase Obligation PurchaseObligation	3206000	USD
CY2018Q3	us-gaap	Purchase Obligation Due After Fifth Year PurchaseObligationDueAfterFifthYear	0	USD
CY2018Q3	us-gaap	Purchase Obligation Due In Fifth Year PurchaseObligationDueInFifthYear	644000	USD
CY2018Q3	us-gaap	Purchase Obligation Due In Fourth Year PurchaseObligationDueInFourthYear	644000	USD
CY2018Q3	us-gaap	Purchase Obligation Due In Next Twelve Months PurchaseObligationDueInNextTwelveMonths	526000	USD
CY2018Q3	us-gaap	Purchase Obligation Due In Second Year PurchaseObligationDueInSecondYear	711000	USD
CY2018Q3	us-gaap	Purchase Obligation Due In Third Year PurchaseObligationDueInThirdYear	681000	USD
CY2017Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2919000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	9357000	USD
CY2018Q3	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3113000	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	10581000	USD
CY2017Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-360877000	USD
CY2018Q3	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-374256000	USD
CY2017Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	14260000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	40574000	USD
CY2018Q3	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	22484000	USD
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	59522000	USD
CY2017Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	8186000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	25427000	USD
CY2018Q3	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	12569000	USD
	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	35314000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	2053000	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	5739000	USD
CY2017Q4	us-gaap	Short Term Investments ShortTermInvestments	0	USD
CY2018Q3	us-gaap	Short Term Investments ShortTermInvestments	44462000	USD
	us-gaap	Stock Issued1 StockIssued1	38389000	USD
	us-gaap	Stock Issued1 StockIssued1	0	USD
	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2700000	USD
CY2017Q4	us-gaap	Stockholders Equity StockholdersEquity	22540000	USD
CY2018Q3	us-gaap	Stockholders Equity StockholdersEquity	94475000	USD
CY2017Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	397000	USD
CY2018Q3	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	302000	USD
CY2017Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	33667000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32783000	shares
CY2018Q3	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	42925000	shares
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	39163000	shares
	us-gaap	Basis Of Accounting BasisOfAccounting	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Basis of Presentation</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The condensed consolidated financial statements included herein have been prepared in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC).  The preparation of condensed consolidated financial statements in conformity with generally accepted accounting principles in the United States of America (U.S. GAAP) requires management to make estimates, judgments, and assumptions that may affect the reported amounts of assets, liabilities, equity, revenues and expenses. Certain information and footnote disclosures normally included in financial statements prepared in accordance with U.S. GAAP have been omitted pursuant to such rules and regulations. The financial statements reflect, in the opinion of management, all adjustments (consisting only of normal, recurring adjustments) necessary to state fairly the financial position and results of operations as of and for the periods indicated.  The results of operations for the </font><font style="font-family:inherit;font-size:10pt;">three and nine</font><font style="font-family:inherit;font-size:10pt;"> months ended </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;">, are not necessarily indicative of the results to be expected for the full year or for any other period. The </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> condensed consolidated balance sheet data was derived from the Company’s audited consolidated financial statements, but does not include all disclosures required by U.S. GAAP.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">These condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended </font><font style="font-family:inherit;font-size:10pt;">December 31, 2017</font><font style="font-family:inherit;font-size:10pt;">, as filed with the SEC on March 5, 2018 (Annual Report).</font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Consolidated Statement of Cash Flows</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">The following table presents certain supplementary cash flows information for the </font><font style="font-family:inherit;font-size:10pt;">nine months ended</font><font style="font-family:inherit;font-size:10pt;"> </font><font style="font-family:inherit;font-size:10pt;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;"> and </font><font style="font-family:inherit;font-size:10pt;">2017</font><font style="font-family:inherit;font-size:10pt;">:</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:681px;border-collapse:collapse;text-align:left;"><tr><td colspan="9" rowspan="1"></td></tr><tr><td style="width:522px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:54px;" rowspan="1" colspan="1"></td><td style="width:11px;" rowspan="1" colspan="1"></td><td style="width:5px;" rowspan="1" colspan="1"></td><td style="width:9px;" rowspan="1" colspan="1"></td><td style="width:60px;" rowspan="1" colspan="1"></td><td style="width:4px;" rowspan="1" colspan="1"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="7" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">Nine Months Ended September 30, 2018</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">(In thousands)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2018</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="text-align:center;font-size:8pt;"><font style="font-family:inherit;font-size:8pt;font-weight:bold;">2017</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:9pt;"><font style="font-family:inherit;font-size:9pt;font-style:normal;">Supplementary Cash Flows information:</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Warrants exercised for common stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:top;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">3,538</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">$</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-top:2px;padding-bottom:2px;" rowspan="1" colspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Interest paid (net of interest capitalized)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:top;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">1,161</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">691</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;background-color:#cceeff;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Shares converted to common from preferred stock</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">—</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;background-color:#cceeff;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">38,389</font></div></td><td style="vertical-align:bottom;background-color:#cceeff;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:12px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Additions to equipment in process included in accounts payable</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">191</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;" rowspan="1" colspan="1"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;" rowspan="1"><div style="text-align:right;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">486</font></div></td><td style="vertical-align:bottom;" rowspan="1" colspan="1"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br clear="none"/></font></div></td></tr></table></div></div></div>
	us-gaap	Nature Of Operations NatureOfOperations	<div style="font-family:Times New Roman;font-size:10pt;"><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Organization</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Vericel Corporation, a Michigan corporation (together with its consolidated subsidiaries referred to herein as the Company, Vericel, we, us or our), was incorporated in March 1989 and began employee-based operations in 1991. On May 30, 2014, Vericel completed the acquisition of certain assets and assumed certain liabilities of Sanofi, a French </font><font style="font-family:inherit;font-size:10pt;font-style:italic;">société anonyme</font><font style="font-family:inherit;font-size:10pt;"> (Sanofi), including all of the outstanding equity interests of Genzyme Biosurgery ApS (Genzyme Denmark or the Danish subsidiary) (now known as Vericel Denmark ApS), a wholly-owned subsidiary of Sanofi, and a portfolio of patents and patent applications of Sanofi and certain of its subsidiaries for purposes of acquiring the portion of the cell therapy and regenerative medicine business (the CTRM Business), related to the MACI</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;">, Carticel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> and Epicel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> products. The Company is a fully integrated, commercial-stage biopharmaceutical company and currently markets MACI</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> and Epicel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> in the U.S. The Company is a leader in advanced cell therapies for the sports medicine and severe burn care markets and a developer of patient-specific expanded cell therapies for use in the treatment of patients with severe diseases and conditions. MACI</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (autologous cultured chondrocytes on porcine collagen membrane) is an autologous cellularized scaffold product indicated for the repair of symptomatic, single or multiple full-thickness cartilage defects of the knee with or without bone involvement in adults that was approved by the FDA on December 13, 2016. The first shipment and implantation of MACI occurred on January 31, 2017. At the end of the second quarter of 2017, the Company removed MACI’s predecessor, Carticel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (autologous cultured chondrocytes), from the market. Carticel is an autologous chondrocyte implant indicated for the repair of symptomatic cartilage defects of the femoral condyle (medial, lateral or trochlea), caused by acute or repetitive trauma, in patients who have had an inadequate response to a prior arthroscopic or other surgical repair procedure (e.g., debridement, microfracture, drilling/abrasion arthroplasty, or osteochondral allograft/autograft). The Company also markets Epicel</font><font style="font-family:inherit;font-size:10pt;"><sup style="vertical-align:top;line-height:120%;font-size:7pt">®</sup></font><font style="font-family:inherit;font-size:10pt;"> (cultured epidermal autografts), a permanent skin replacement Humanitarian Use Device (HUD) for the treatment of patients with deep-dermal or full-thickness burns comprising greater than or equal to 30 percent of total body surface area (TBSA). The Company operates its business primarily in the U.S. in </font><font style="font-family:inherit;font-size:10pt;">one</font><font style="font-family:inherit;font-size:10pt;"> reportable segment — the research, product development, manufacture and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.</font></div><div style="line-height:120%;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"> </font></div><div style="line-height:120%;text-align:justify;text-indent:18px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;color:#222222;">The accompanying condensed consolidated financial statements have been prepared on a basis, which assumes that the Company will continue as a going concern and contemplates the realization of assets and satisfaction of liabilities and commitments in the normal course of business.  As of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#222222;">, the Company has an accumulated deficit of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$374.3 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> and had a net loss of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$1.1 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> during the quarter ended </font><font style="font-family:inherit;font-size:10pt;color:#222222;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#222222;">.  The Company had cash and cash equivalents of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$53.3 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;">, and short term investments of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">$44.5 million</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> as of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#222222;">.  The Company expects that existing cash, cash equivalents and short term investments together with its </font><font style="font-family:inherit;font-size:10pt;">term loan and revolving line of credit agreement with Silicon Valley Bank (SVB) and MidCap Financial Services (MidCap) (the</font><font style="font-family:inherit;font-size:10pt;color:#222222;"> SVB-MidCap facility), will be sufficient to support the Company's </font><font style="font-family:inherit;font-size:10pt;">current operations through at least </font><font style="font-family:inherit;font-size:10pt;">November 2019</font><font style="font-family:inherit;font-size:10pt;color:#222222;">.  In connection with the SVB-MidCap facility, </font><font style="font-family:inherit;font-size:10pt;">the Company must remain in compliance with minimum monthly net revenue covenants (determined in accordance with U.S. GAAP), measured on a trailing twelve month basis. </font><font style="font-family:inherit;font-size:10pt;color:#222222;">SVB and MidCap also have the ability to call debt based on material adverse change clauses, which are subjectively determinable and result in a </font><font style="font-family:inherit;font-size:10pt;">subjective acceleration clause. </font><font style="font-family:inherit;font-size:10pt;color:#222222;">If the Company is not in compliance with the monthly net revenue covenants or the subjective acceleration clauses are triggered under the SVB-MidCap facility, then SVB may call the debt.  As of </font><font style="font-family:inherit;font-size:10pt;color:#222222;">September 30, 2018</font><font style="font-family:inherit;font-size:10pt;color:#222222;">, the Company was in compliance with the minimum revenue covenant set forth in the Third Loan Modification Agreement between the Company, SVB and MidCap. The Company may seek additional funding through debt or equity financings.  However, the Company may not be able to obtain financing on acceptable terms or at all. The terms of any financing may adversely affect the holdings or the rights of the Company's shareholders.</font></div></div>

Files In Submission

Name	View Source	Status
0001628280-18-013767-index-headers.html	Edgar Link	pending
0001628280-18-013767-index.html	Edgar Link	pending
0001628280-18-013767.txt	Edgar Link	pending
0001628280-18-013767-xbrl.zip	Edgar Link	pending
a101redactedfinalvericel-f.htm	Edgar Link	pending
a102redactedversionfinal72.htm	Edgar Link	pending
a103redactedvericelfiftham.htm	Edgar Link	pending
astm-20180930.xml	Edgar Link	completed
astm-20180930.xsd	Edgar Link	pending
astm-20180930_cal.xml	Edgar Link	unprocessable
astm-20180930_def.xml	Edgar Link	unprocessable
astm-20180930_lab.xml	Edgar Link	unprocessable
astm-20180930_pre.xml	Edgar Link	unprocessable
ex311q32018-ceocertificati.htm	Edgar Link	pending
ex312q32018-cfocertificati.htm	Edgar Link	pending
ex321q32018-ceosoxcertific.htm	Edgar Link	pending
ex322q32018-cfosoxcertific.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
vericel9301810q.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$VCEL
Vericel Corp Stock $vcel

2018 Q4 Form 10-Q Financial Statement

#000162828018013767 Filed on November 06, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL Vericel Corp Stock $vcel

2018 Q4 Form 10-Q Financial Statement

#000162828018013767 Filed on November 06, 2018

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$VCEL
Vericel Corp Stock $vcel